Published in Angiogenesis on March 11, 2010
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene (2011) 1.10
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate. Angiogenesis (2011) 0.93
Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Mol Oncol (2011) 0.84
Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice. PLoS One (2013) 0.80
Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer (2015) 0.75
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther (1999) 7.96
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15
The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71
Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
von Hippel-Lindau disease. Medicine (Baltimore) (1997) 2.89
Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med (2006) 2.65
PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A (2008) 1.92
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Efficiency of recombination by Cre transient expression in embryonic stem cells: comparison of various promoters. J Biochem (1997) 1.68
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev (2003) 1.56
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res (2003) 1.46
Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer (2002) 1.31
In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res (2004) 1.20
Case report: multiple hepatic and pulmonary haemangioblastomas--a new manifestation of von Hippel-Lindau disease. Clin Radiol (1992) 1.13
Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res (1995) 1.10
Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol (2004) 1.04
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther (2008) 1.00
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene (2009) 0.96
VHL: oxygen sensing and vasculogenesis. J Thromb Haemost (2005) 0.87
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Production and characterization of adeno-associated viral vectors. Nat Protoc (2006) 4.11
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med (2003) 2.70
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol (2007) 2.69
Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol (2006) 2.63
Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol (2011) 2.55
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 2.36
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology (2009) 2.25
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab (2013) 1.93
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther (2007) 1.85
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell (2003) 1.85
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood (2008) 1.72
Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol (2004) 1.64
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther (2009) 1.61
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest (2007) 1.56
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A (2009) 1.53
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther (2011) 1.53
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol (2007) 1.52
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology (2008) 1.51
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol (2008) 1.50
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell (2002) 1.48
Renal cell carcinoma. Curr Opin Oncol (2008) 1.47
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol (2008) 1.44
Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol (2006) 1.43
Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol (2010) 1.42
Sensing of intermediates in V(D)J recombination by ATM. Genes Dev (2002) 1.42
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol (2010) 1.37
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res (2013) 1.31
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res (2012) 1.30
Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther (2009) 1.28
pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol (2004) 1.27
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res (2005) 1.24
Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol (2003) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res (2009) 1.23
Long-term follow-up after gene therapy for canavan disease. Sci Transl Med (2012) 1.22
Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol (2010) 1.21
Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology (2012) 1.21
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol (2012) 1.19
Basic research in kidney cancer. Eur Urol (2011) 1.19
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther (2009) 1.18
Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther (2012) 1.16
Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther (2010) 1.16
Conformational changes of NADPH-cytochrome P450 oxidoreductase are essential for catalysis and cofactor binding. J Biol Chem (2011) 1.15
Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol (2005) 1.15
Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A (2011) 1.14
Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice. Mol Cancer Res (2003) 1.14
Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. Proc Natl Acad Sci U S A (2007) 1.13
p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol (2002) 1.12
Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res (2005) 1.10
Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther (2011) 1.10
Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther (2004) 1.09
Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol (2012) 1.05
Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation (2003) 1.05
Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci (2007) 1.04
Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol (2012) 1.04
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Surface loop dynamics in adeno-associated virus capsid assembly. J Virol (2008) 1.04
Ethical challenges: managing oncology drug shortages. J Oncol Pract (2013) 1.03
Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol (2013) 1.01
Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol (2013) 1.01
Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther (2013) 1.00
Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther (2008) 1.00
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol (2012) 0.99
Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv (2010) 0.98
Adeno-associated virus vectors for therapeutic gene transfer. Biotechniques (2003) 0.98
Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol (2003) 0.98
Renal cell carcinoma: where will the state-of-the-art lead us? Curr Oncol Rep (2010) 0.97
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol (2009) 0.97
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther (2015) 0.97